Clinical trial
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for…
NCT00300508 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00300508 |
|---|---|
| Title | 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer |
| Official title | A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Anastrozole |
| Enrollment | 856 |
| Start date | Jan 1, 1996 |
| First posted | Mar 9, 2006 |
| Last update posted | May 1, 2009 |
| Countries | Austria |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: